Key takeaways
- $2.2–3.1M one-time list price for Casgevy and Lyfgenia — among the highest-cost US therapies · manufacturer list prices
- CGTA CMS Cell & Gene Therapy Access Model — Medicaid outcomes-based contracts tied to VOC-freedom milestones · CMS 2024
- 25–30% eligible patients on hydroxyurea — the low-cost step-edit prerequisite before gene-therapy authorisation · ASH guidelines
Two multimillion-dollar one-time cures meet a Medicaid-dominant patient population — and CMS's Cell & Gene Therapy Access Model ties payment to durable vaso-occlusive-crisis freedom.
The US sickle cell payer question is defined by two one-time gene therapies priced near $2.2M (Casgevy) and $3.1M (Lyfgenia) entering a population concentrated in Medicaid — SCD is disproportionately borne in Medicaid-heavy Southern states. To make these therapies payable, CMS launched the Cell & Gene Therapy Access Model in 2024, enabling state Medicaid programs to enter voluntary outcomes-based contracts in which manufacturer payments are tied to durable vaso-occlusive-crisis freedom, with a best-price rebate waiver to permit outcome-linked payment.
Two frictions shape access. First, Lyfgenia's FDA boxed warning for hematologic malignancy has driven a formulary split, with major plans positioning Casgevy as preferred within the gene-therapy class. Second, payers universally require a documented hydroxyurea trial at maximum tolerated dose for at least six months before authorising gene therapy — a roughly $600-a-year prerequisite for a multimillion-dollar treatment. Because only 25–30% of eligible patients are on hydroxyurea, many must initiate and complete this step-edit first, adding months to an already complex pathway of qualified-center referral, apheresis and myeloablative conditioning.
US sickle cell disease agent access — pricing, mechanism and PA criteria
| Drug (Brand / INN) | Access Route | List Price | Payer Access Mechanism | Key Endpoint / PA Criterion |
|---|---|---|---|---|
| Casgevy (exagamglogene autotemcel) | One-time; qualified treatment center; CGTA-eligible | ~$2.2M | Medicaid outcomes-based contract (CGTA); preferred within gene-therapy class | Severe VOC freedom ≥12 months (CLIMB SCD-121); PA: ≥2 severe VOCs/yr, hydroxyurea at MTD ≥6 months |
| Lyfgenia (lovotibeglogene autotemcel) | One-time; qualified treatment center; CGTA-eligible | ~$3.1M | Boxed warning drives formulary hesitancy; often non-preferred vs Casgevy | Complete resolution of vaso-occlusive events (FDA label); PA adds documented hematologic-malignancy risk discussion |
| Hydroxyurea (generic) | Part D / pharmacy; no PA | ~$600–1,200/yr | Universal step-edit prerequisite before gene-therapy authorisation | Documented trial at maximum tolerated dose ≥6 months |
| Adakveo (crizanlizumab) | Part B medical benefit (IV, monthly) | High-cost specialty | Standard medical-benefit coverage; VOC-rate reduction endpoint (SUSTAIN) | PA: recurrent VOCs; post-approval STAND trial did not confirm benefit |
| Endari (L-glutamine) | Part D / pharmacy | Chronic oral | Standard specialty PA | Reduction in sickle-cell crisis frequency |
Sources: CMS Cell and Gene Therapy Access Model (2024); FDA product labeling (Casgevy, Lyfgenia, Adakveo, Endari); CLIMB SCD-121, NEJM 2024 (PMID 38661449); ASH 2020 SCD guidelines. Gene-therapy list prices per manufacturer announcements.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- How are Casgevy and Lyfgenia paid for, and how does the CMS Cell & Gene Therapy Access Model structure Medicaid access? • $2.2–3.1M one-time pricing • CGTA outcomes-based Medicaid contracts • VOC-freedom milestone endpoints • the best-price rebate waiver • high-burden state prioritisation
- How does Lyfgenia's boxed warning shape the formulary split, and where is Casgevy preferred? • Boxed warning for hematologic malignancy • commercial-plan preferred/non-preferred positioning within the gene-therapy class • PA documentation differences
- What prior-authorisation and step-edit criteria gate gene-therapy access? • Universal hydroxyurea MTD trial (≥6 months) • severe-disease threshold (≥2 VOCs/year) • qualified-center requirement • the access-lag effect of the 25–30% hydroxyurea gap
What's inside
-
1 · US Payer Landscape — SCD Coverage Architecture 4 pp
- Two one-time gene therapies priced near $2.2M (Casgevy) and $3.1M (Lyfgenia) enter a population disproportionately concentrated in Medicaid-heavy Southern states
- How CMS designed the Cell & Gene Therapy Access Model specifically to make these multimillion-dollar therapies payable within state Medicaid budgets
-
2 · Gene-Therapy Pricing & the CMS Cell & Gene Therapy Access Model 6 pp
- CMS launched the Cell & Gene Therapy Access Model in 2024, enabling state Medicaid programs to enter voluntary outcomes-based contracts for Casgevy and Lyfgenia
- A CMS best-price rebate waiver permits outcome-linked payment, the same mechanism that first enabled Zolgensma's Medicaid contracting in SMA
-
3 · Outcomes-Based Contracting & VOC-Freedom Endpoints 4 pp
- Manufacturer payments under CGTA contracts are tied to durable vaso-occlusive-crisis freedom, mirroring the CLIMB SCD-121 endpoint used in Casgevy's approval
- How outcomes-based structures let Medicaid programs hedge the one-time gene-therapy price against real-world durability of effect
-
4 · Lyfgenia Boxed Warning & the Formulary Split 3 pp
- Lyfgenia's FDA boxed warning for hematologic malignancy has driven a formulary split, with major plans positioning Casgevy as preferred within the gene-therapy class
- Prior authorization for Lyfgenia adds a documented hematologic-malignancy risk discussion absent from the Casgevy pathway
-
5 · Hydroxyurea Step-Edit & Prior-Authorisation Criteria 4 pp
- Payers universally require a documented hydroxyurea trial at maximum tolerated dose for at least six months before authorising gene therapy, a roughly $600-a-year prerequisite
- Because only 25–30% of eligible patients are already on hydroxyurea, many must initiate and complete this step-edit first, adding months to the gene-therapy pathway
-
6 · Medicaid Concentration & Site-of-Care Logistics 4 pp
- SCD's Medicaid-heavy Southern-state concentration means state budget capacity, not just clinical eligibility, shapes gene-therapy access timelines
- Qualified-center referral, apheresis and myeloablative conditioning form a multi-month site-of-care logistics chain layered on top of payer authorisation
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx US Sickle Cell Disease Payer & HTA is built for market access, HEOR, and pricing teams navigating gene-therapy pricing, the CMS access model, and step-edit criteria. Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, payer focus (pricing, CMS model, PA criteria), and commercial question.
- 2. Scoping callAXLRx analyst confirms payer scope, access model, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx assessment is built from primary regulatory sources (FDA Drugs@FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer and HTA documentation — not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
US Sickle Cell Disease Payer & HTA sources: the CMS Cell & Gene Therapy Access Model documentation, FDA product labeling, manufacturer list-price announcements, ASH 2020 SCD treatment guidelines, and live commercial and Medicaid coverage-policy documents.
- Gene-therapy FDA status and indications verified live against FDA product labeling (Casgevy, Lyfgenia)
- exa-cel VOC-freedom endpoint verified against CLIMB SCD-121, N Engl J Med 2024 (PMID 38661449)
- CMS Cell & Gene Therapy Access Model structure verified against the CMS 2024 model announcement
- Hydroxyurea step-edit and utilisation gap cross-referenced against ASH 2020 SCD guidelines and the Multicenter Study of Hydroxyurea, NEJM 1995 (PMID 7715639)
Frequently asked questions
Access How is sickle cell gene therapy paid for in the US?
Casgevy and Lyfgenia carry one-time list prices near $2.2M and $3.1M and are paid largely through Medicaid, since SCD is concentrated in Medicaid-heavy states. CMS's Cell & Gene Therapy Access Model lets state Medicaid programs enter outcomes-based contracts with manufacturer payments tied to durable vaso-occlusive-crisis freedom.
Prior authorization What must a patient try before gene therapy is approved?
Payers universally require a documented trial of hydroxyurea at maximum tolerated dose for at least six months, plus severe disease (typically ≥2 vaso-occlusive crises per year) and treatment at a qualified center. Because only 25–30% of eligible patients are on hydroxyurea, many must complete this step-edit first — adding months to the access pathway.
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model, and a 10–15 slide PowerPoint readout deck. An optional 60-minute analyst readout call is included with all deliveries.